RE: Hardman report30 Jun 2021 17:56
Have gone through the current material fairly thoroughly. Had taken up a mere 75k but after further study am inclined to believing the North American market (incl. Canada, Mexico and US) could perform better than expected during H2. It is assumed all necessary approvals have been obtained in each country.
Transforming "the treatment of patients in key surgical applications: BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology, and Cardiac" disciplines is a comprehensive exercise.
A great deal of effort has gone into conveying the message this year. After further examination I believe my initial stock buy was too light and shall add a further wedge tomorrow.